{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":3,"sponsored":0,"items":[{"id":"n_uhsbqowspqlbg244jqxq","seq":11084316,"kind":"article","title":"Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer","url":"https://www.2minutemedicine.com/durvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer","published":"2026-11-14T14:54:00Z","seen":"2026-11-14T14:54:00Z","lang":"en","source":{"id":"2minutemedicine.com","name":"2minutemedicine.com","domain":"2minutemedicine.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"authors":["2 Minute Medicine","Reviewed Marc Succi","MD (Harvard Medical School)"],"entities":[{"id":"Q19904005","name":"durvalumab","type":"other"},{"id":"Q19904068","name":"enfortumab vedotin","type":"other"}],"story":"st_gxlyph6yblx23rm3m2eq","category":"health","category_p":0.6,"sentiment":"neutral","tone":0.18,"political":0.12},{"id":"n_ebbsce7brq6jr2ffamzq","seq":4137542,"kind":"article","title":"ESMO 2026: ctDNA Analysis of the Phase 3 KEYNOTE-B15 Trial: Neoadjuvant and Adjuvant Enfortumab Vedotin Plus Pembrolizumab for Participants With Muscle-Invasive Bladder Cancer Who Are Eligible for Cisplatin","url":"https://www.urotoday.com/conference-highlights/esmo-2026/esmo-2026-bladder-cancer/172703-esmo-2026-ctdna-analysis-of-the-phase-3-keynote-b15-trial.html","published":"2026-10-24T02:00:00Z","seen":"2026-10-24T02:07:30Z","lang":"en","source":{"id":"urotoday.com","name":"urotoday.com","domain":"urotoday.com","outlet":{"wikidata":"Q96334749","name":"UroToday International Journal","type":"other","designations":["scientific journal"]}},"via":"gdelt-gkg-english","topics":["economy","health","education","politics"],"entities":[{"id":"Q19904068","name":"enfortumab vedotin","type":"other"},{"id":"Q13896859","name":"pembrolizumab","type":"other"},{"id":"Q3182853","name":"plastome","type":"other"}],"story":"st_ebbsce7brq6jr2ffamzq","category":"health","category_p":0.48,"category2":"science-technology","sentiment":"neutral","tone":-0.14,"political":0.09},{"id":"n_otz6ixqmcmurpwz62jgq","seq":4098949,"kind":"article","title":"ESMO 2026: EV-309: An Open-Label, Randomized, Phase 3 Study of Enfortumab Vedotin + Pembrolizumab for Bladder Preservation in Patients with MIBC","url":"https://www.urotoday.com/conference-highlights/esmo-2026/esmo-2026-bladder-cancer/172686-esmo-2026-ev-309-an-open-label-randomized-phase-3-study-of-enfortumab-vedotin-pembrolizumab-for-bladder-preservation-in-patients-with-mibc.html","published":"2026-10-23T22:21:00Z","seen":"2026-10-23T22:21:00Z","lang":"en","source":{"id":"urotoday.com","name":"urotoday.com","domain":"urotoday.com","outlet":{"wikidata":"Q96334749","name":"UroToday International Journal","type":"other","designations":["scientific journal"]}},"via":"gdelt-gkg-english","topics":["economy","education","health"],"entities":[{"id":"Q135889520","name":"ESMO","type":"org"},{"id":"Q19904068","name":"enfortumab vedotin","type":"other"},{"id":"Q13896859","name":"pembrolizumab","type":"other"},{"id":"Q2528979","name":"4-methyl-2-pentanol","type":"other"}],"story":"st_otz6ixqmcmurpwz62jgq","category":"health","category_p":0.71,"sentiment":"neutral","tone":-0.16,"political":0.04}]}